Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$146.64
-2.9%		$137.57
$108.46
▼
$157.29
$187.23B0.335.03 million shs6.08 million shs
Natera, Inc. stock logo
NTRA
Natera
$324.14
-1.2%		$294.79
$157.43
▼
$343.18
$47.31B1.541.17 million shs1.03 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$810.31
-2.1%		$745.94
$541.00
▼
$859.34
$85.22B0.2625,299 shs556,467 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$528.90
-3.2%		$511.07
$374.17
▼
$560.25
$138.61B0.32983,570 shs1.12 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-2.88%-2.19%+10.08%+20.71%+26.54%
Natera, Inc. stock logo
NTRA
Natera
-1.23%+1.05%+0.63%+49.72%+93.64%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-2.10%-1.64%+3.31%+34.68%+45.10%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-3.15%-3.42%+6.62%+21.39%+33.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$146.64
-2.9%		$137.57
$108.46
▼
$157.29
$187.23B0.335.03 million shs6.08 million shs
Natera, Inc. stock logo
NTRA
Natera
$324.14
-1.2%		$294.79
$157.43
▼
$343.18
$47.31B1.541.17 million shs1.03 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$810.31
-2.1%		$745.94
$541.00
▼
$859.34
$85.22B0.2625,299 shs556,467 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$528.90
-3.2%		$511.07
$374.17
▼
$560.25
$138.61B0.32983,570 shs1.12 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-2.88%-2.19%+10.08%+20.71%+26.54%
Natera, Inc. stock logo
NTRA
Natera
-1.23%+1.05%+0.63%+49.72%+93.64%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-2.10%-1.64%+3.31%+34.68%+45.10%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-3.15%-3.42%+6.62%+21.39%+33.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.86
Moderate Buy$158.047.77% Upside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$322.50-0.51% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.58
Moderate Buy$800.36-1.23% Downside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$569.527.68% Upside

Current Analyst Ratings Breakdown

Latest NTRA, GILD, VRTX, and REGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Buy
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$665.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$653.00
8/31/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/25/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/17/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$641.00 ➝ $824.00
8/13/2026
Natera, Inc. stock logo
NTRA
Natera
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$315.00 ➝ $365.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$305.00 ➝ $350.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $360.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B6.18$10.17 per share14.42$18.23 per share8.04
Natera, Inc. stock logo
NTRA
Natera
$2.31B20.26N/AN/A$12.38 per share26.18
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.82$41.09 per share19.72$295.66 per share2.74
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.59B10.66$17.02 per share31.07$73.57 per share7.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$2.67N/A14.86N/A-10.64%-2.11%-0.75%10/29/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A32,414.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4620.0316.041.6227.86%13.47%10.34%10/28/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1830.7928.712.3735.00%23.09%16.72%11/2/2026 (Estimated)

Latest NTRA, GILD, VRTX, and REGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/3/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.25-$6.75+$0.50-$8.45$7.40 billion$7.80 billion
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.24%+3.04%N/A 10 Years
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.46%N/A9.29%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest NTRA, GILD, VRTX, and REGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.43%9/15/20269/15/20269/29/2026
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.03
1.27
1.09
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.81 million253.30 millionOptionable

Recent News About These Companies

Carmignac Gestion Has $81 Million Position in Vertex Pharmaceuticals Incorporated $VRTX
September 8 at 7:11 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-carmignac-gestion-has-81-million-position-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-08/
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
September 8 at 6:50 PM  |  zacks.comhttps://www.zacks.com/stock/news/2986677/vertex-pharmaceuticals-vrtx-suffers-a-larger-drop-than-the-general-market-key-insights?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2986677
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
September 8 at 6:31 PM  |  fool.comhttps://www.fool.com/investing/2026/09/08/goldman-sachs-just-added-vertex-pharmaceuticals-to/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=a98a37ab-4495-40c2-ac9a-0f4d7a88160b
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
September 8 at 6:29 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-vrtx-suffers-larger-215004539.html
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
September 8 at 6:29 PM  |  fool.comhttps://www.fool.com/investing/2026/09/08/goldman-sachs-just-added-vertex-pharmaceuticals-to/
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
September 8 at 1:28 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/investors-heavily-search-vertex-pharmaceuticals-130003081.html
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
September 8 at 10:01 AM  |  zacks.comhttps://www.zacks.com/stock/news/2986234/investors-heavily-search-vertex-pharmaceuticals-incorporated-vrtx-here-is-what-you-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks_v1-2986234
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Sold Rep. David Taylor
September 8 at 2:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-vertex-pharmaceuticals-nasdaq-vrtx-stock-sold-rep-david-taylor-2026-09-08/
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
September 7 at 2:30 PM  |  247wallst.comhttps://247wallst.com/investing/etf/2026/09/07/ibb-just-beat-the-sp-500-by-22-points-in-three-months-are-you-late-to-the-party/
Rep. David Taylor discloses 6 new Congressional stock trades
September 7 at 2:10 PM  |  finbold.comF
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 94,060 Vertex Pharmaceuticals Incorporated $VRTX
September 7 at 6:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-buys-shares-of-94060-vertex-pharmaceuticals-incorporated-vrtx-2026-09-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Hsbc Holdings PLC
September 7 at 4:48 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-acquired-by-hsbc-holdings-plc-2026-09-07/
2,409 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Formuepleje A S
September 7 at 4:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2409-shares-in-vertex-pharmaceuticals-incorporated-vrtx-purchased-by-formuepleje-a-s-2026-09-07/
California State Teachers Retirement System Buys 190,118,003 Shares of Vertex Pharmaceuticals Incorporated $VRTX
September 7 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-190118003-shares-of-vertex-pharmaceuticals-incorporated-vrtx-2026-09-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Amundi
September 7 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-purchased-by-amundi-2026-09-07/
Saudi Central Bank Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
September 6 at 5:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-saudi-central-bank-raises-stock-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-06/
AXQ Capital LP Buys New Holdings in Vertex Pharmaceuticals Incorporated $VRTX
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-axq-capital-lp-buys-new-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-09-05/
NEOS Investment Management LLC Purchases 19,219 Shares of Vertex Pharmaceuticals Incorporated $VRTX
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-neos-investment-management-llc-purchases-19219-shares-of-vertex-pharmaceuticals-incorporated-vrtx-2026-09-04/
Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 12-Month High - Here's What Happened
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003212
Nykredit A S Buys Shares of 248,068 Vertex Pharmaceuticals Incorporated $VRTX
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-buys-shares-of-248068-vertex-pharmaceuticals-incorporated-vrtx-2026-09-03/
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
September 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2983858/why-is-vertex-vrtx-up-14-4-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2983858

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illustration showing Hims & Hers logo and app connected through a security checkpoint icon to the Visa logo and card.
Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
By Jeffrey Neal Johnson | August 24, 2026
Illustration of a glass globe surrounded by gold coin stacks, symbolizing global financial markets and investment.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
By Jessica Mitacek | August 17, 2026
IonQ logo displayed within an illuminated glass chamber surrounded by a futuristic space-themed backdrop.
IonQ’s Space Contract Points to a New Frontier for Quantum Investors
By Nathan Reiff | August 19, 2026
Illustration of a glowing digital shield and lock blocking red virus icons in a server data center.
3 Ways to Invest in Cybersecurity Through ETFs
By Dan Schmidt | August 20, 2026
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts
By Ryan Hasson | August 22, 2026
Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$146.64 -4.35 (-2.88%)
Closing price 09/8/2026 04:00 PM Eastern
Extended Trading
$146.16 -0.48 (-0.33%)
As of 09/8/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Natera stock logo

Natera NASDAQ:NTRA

$324.14 -4.04 (-1.23%)
Closing price 09/8/2026 04:00 PM Eastern
Extended Trading
$328.12 +3.99 (+1.23%)
As of 09/8/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$810.31 -17.41 (-2.10%)
Closing price 09/8/2026 04:00 PM Eastern
Extended Trading
$812.14 +1.84 (+0.23%)
As of 09/8/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$528.90 -17.22 (-3.15%)
Closing price 09/8/2026 04:00 PM Eastern
Extended Trading
$526.95 -1.95 (-0.37%)
As of 09/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas